NCT00520013View on ClinicalTrials.gov

Avastin +/- Erlotinib Consolidation Chemotherapy After Carboplatin, Paclitaxel, and Avastin (CTA) Induction Therapy for Advanced Ovarian, Fallopian Tube, Primary Peritoneal Cancer & Papillary Serous or Clear Cell Mullerian Tumors

PHASE2CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

August 31, 2007

Primary Completion Date

October 31, 2010

Study Completion Date

November 30, 2013

Conditions
Ovarian CancerFallopian Tube CancerPrimary Peritoneal CancerPapillary Serous Mullerian TumorClear Cell Mullerian Tumor
Interventions
DRUG

bevacizumab

DRUG

erlotinib

DRUG

paclitaxel

DRUG

carboplatin

Trial Locations (3)

02114

Massachusetts General Hospital, Boston

02115

Beth Israel Deaconess Medical Center, Boston

Dana-Farber Cancer Institute, Boston

Sponsors

Collaborators (1)

Genentech, Inc.
All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

collaborator

Beth Israel Deaconess Medical Center

OTHER

collaborator

Brigham and Women's Hospital

OTHER

collaborator

Massachusetts General Hospital

OTHER

lead

Dana-Farber Cancer Institute

OTHER